CUREVAC N V's ticker is CVAC and the CUSIP is N2451R105. A total of 117 filers reported holding CUREVAC N V in Q3 2021. The put-call ratio across all filers is 2.16 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,349,193 | -37.6% | 1,808,081 | -4.8% | 0.01% | -40.0% |
| Q2 2023 | $19,787,153 | +158476.3% | 1,898,959 | +6.1% | 0.01% | +42.9% |
| Q1 2023 | $12,478 | +138.9% | 1,790,308 | +106.7% | 0.01% | +133.3% |
| Q4 2022 | $5,223 | -99.9% | 866,244 | +61.6% | 0.00% | +50.0% |
| Q3 2022 | $4,224,000 | -41.9% | 536,032 | +0.3% | 0.00% | -60.0% |
| Q2 2022 | $7,270,000 | -36.0% | 534,201 | -7.7% | 0.01% | -16.7% |
| Q1 2022 | $11,352,000 | +35.8% | 578,902 | +137.6% | 0.01% | +50.0% |
| Q4 2021 | $8,358,000 | -42.2% | 243,615 | -8.0% | 0.00% | -55.6% |
| Q3 2021 | $14,470,000 | -64.4% | 264,922 | -52.1% | 0.01% | -62.5% |
| Q2 2021 | $40,598,000 | +121.7% | 552,507 | +175.9% | 0.02% | +71.4% |
| Q1 2021 | $18,314,000 | +1751.8% | 200,235 | +1540.6% | 0.01% | +1300.0% |
| Q4 2020 | $989,000 | -93.0% | 12,205 | -96.0% | 0.00% | -94.1% |
| Q3 2020 | $14,181,000 | – | 304,637 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bill & Melinda Gates Foundation | 3,134,780 | $286,707,000 | 46.92% |
| Ally Bridge Group (NY) LLC | 110,000 | $10,061,000 | 1.93% |
| Parametrica Management Ltd | 44,695 | $3,968,000 | 1.91% |
| Renaissance Capital LLC | 123,983 | $11,339,000 | 1.68% |
| Samsara BioCapital, LLC | 95,318 | $8,718,000 | 1.61% |
| Ikarian Capital, LLC | 360,000 | $32,925,000 | 1.11% |
| SECTOR GAMMA AS | 25,000 | $2,287,000 | 0.42% |
| Fosun International Ltd | 50,000 | $4,438,000 | 0.35% |
| Ikarian Capital, LLC | 100,000 | $9,145,000 | 0.31% |
| Baillie Gifford | 5,830,101 | $533,221,000 | 0.30% |